1.

MATTERS OF ADMINISTRATION

1.1

Welcome and apologies

1.2

Minutes and recommendations of the 195th MARC meeting

1.3

Declarations of potential competing interests

2.

MATTERS ARISING FROM THE NZ PHARMACOVIGILANCE CENTRE

2.1

CARM quarterly report

3.

PHARMACOVIGILANCE REPORTS

3.1

Matters referred to the MARC under section 36 of the Medicines Act 1981

No items

3.2

Matters referred to the MARC by Medsafe

3.2.1 Direct-acting oral anticoagulants (DOACs) and anticoagulant-related nephropathy (ARN)

3.2.2 Potential drug interaction between estrogen-based hormone replacement therapy and lamotrigine

3.2.3 Third generation aromatase inhibitors and tendon disorders

3.2.4 Tumour lysis syndrome with tyrosine kinase inhibitors and monoclonal antibodies when used in cancer treatment

4.

MEDSAFE PHARMACOVIGILANCE ACTIVITIES

4.1

Report on standing agenda items

4.2

Medsafe pharmacovigilance activities

4.3

Prescriber Update

4.4

Quarterly summary of recent safety communications